IQVIA closed 2025 with strong performance across all segments, delivering near double-digit revenue and EPS growth. The company reported fourth-quarter revenue of $4,364 million and GAAP diluted EPS of $2.99. R&D Solutions saw its strongest quarter for net bookings, and both commercial and clinical businesses experienced strong topline growth. The company also provided optimistic full-year 2026 guidance.
Fourth-quarter revenue reached $4,364 million, an increase of 10.3% on a reported basis compared to the fourth quarter of 2024.
GAAP diluted earnings per share for the fourth quarter was $2.99, up 23.6% year-over-year.
R&D Solutions quarterly bookings exceeded $2.7 billion, resulting in a book-to-bill ratio of 1.18x.
Full-year 2026 revenue guidance is projected to be between $17,150 million and $17,350 million, with adjusted diluted EPS between $12.55 and $12.85.
For the full year 2026, IQVIA expects revenue to be between $17,150 million and $17,350 million, with Adjusted EBITDA between $3,975 million and $4,025 million, and Adjusted Diluted Earnings per Share between $12.55 and $12.85.
Analyze how earnings announcements historically affect stock price performance